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Abstract
Magnetic and gold coated magnetic nanoparticles were synthesized by co-precipitation of ferrous
and ferric chlorides, and by the micromicelles method, respectively. Synthesized nanoparticles
were functionalized to bear carboxyl and amino acid moieties and used as prion protein carriers
after carbodiimide activation in the presence of N-hydroxysuccinimide. The binding of human
recombinant prion protein (huPrPrec) to the surface of these nanoparticles was confirmed by FTIR
and the size and structures of the particles were characterized by transmission electron
microscopy. Findings indicate that the rate of prion binding increased only slightly when the
concentration of prion in the reaction medium was increased. Rate constants of binding were very
similar on Fe3O4@Au and Fe3O4-LAA when the concentrations of protein were 1, 2, 1.5, 2.25 and
3.57 μg/ml. For a 5 μg/ml concentration of huPrPrec the binding rate constant was higher for the
Fe3O4-LAA particles. This study paves the way towards the formation of prion protein complexes
onto a 3-dimensional structure that could reveal obscure physiological and pathological structure
and prion protein kinetics.
Background
Prion diseases also called Transmissible Spongiform
Encephalopathies (TSE) are a group of degenerative dis-
eases that feature the pronounced accumulation, in cer-
tain brain regions, of a misfolded isomer PrPsc of the
cellular prion protein (PrPc) [1-3]. Spongiform encepha-
lopathy in cattle, scrapie in sheep, Gerstmann-Straussler
Scheinker in human, and Creutzfied-Jacob disease are
caused due to the misfolding of protein denoted as prion
protein [1-4]. Understanding the basis of prion disease
revolves around understanding how the normal protein,
PrPc is converted into its abnormal form, PrPsc. Hypothe-
sis suggest that prion infection is associated with a confor-
mational transition between the two forms [1-5]. In a
broader sense, prions are elements that impart and prop-
agate variability through a multitude of conformations of
normal cellular proteins [6]. However, the mechanism by
which this conversion occurs is not clearly known. Cui et
al. [6] and Spencer et al [7] proposed that this conversion
involves a switch in the conformation from a structure
rich in α-helix to the one rich in β-sheet through a spatial
arrangement and molecule folding.
Protein unfolding is associated with the disruption of
interactions leading to a loss in the secondary structure
(the fold of α-helices, β-strands and turns, and tertiary
structure – the packing of the secondary structural ele-
ments and the amino acid side chains [8]). In the last two
decades a fundamental concern that arose was on the
issues of prion related diseases. For example, meat
exported from UK has been banned by a number of coun-
tries as a precautionary measure against Bovine Spongi-
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form Encephalopathy (BSE) after the major outbreak of
mad cow disease in 1996. Although the cause of the infec-
tion remains unknown, it was suggested that meat and
bone meal imported from other countries may have been
incorporated into feed supplements before these coun-
tries could adopt a suitable feed control strategy [9]. In
2003, BSE was detected in one cow in Canada and another
in the U.S which lead to the killing of more than 2700 ani-
mals and subsequent testing to trace the history and
source of contamination [10]. Adequate methods to
detect and screen prion related diseases could prevent the
mass killing of animals while simultaneously ensuring the
safety of animal-based food products. Since identification
and quantification of proteins and their folding mecha-
nism are very important in disease diagnosis, nanotech-
nology based approaches could perhaps be used to
develop detection assays that are very sensitive with abil-
ity to differentiate between structural elements [11].
It is well known that intermolecular covalent cross-linking
of functional groups in proteins has proved to be a very
useful approach in the study of structure-function rela-
tionship in proteins [12]. Furthermore, insights into pro-
tein folding could be better evaluated and the molecule
manipulated via appropriate bioconjugation strategies
using nanotechnology based approaches. Nanostructures
could thus be construed as a natural choice. The structure-
function relationship of proteins or its stability depends
on the combination of several properties which have to be
fulfilled by the amino acid at a certain position in the pro-
tein. For example, a relationship between the stability of
the hydrophobic moieties and the buried residues with
conformational stability has been found [13]. This sug-
gests that the conformation which involves the 3-dimen-
sional arrangement of the protein molecule affects its
functionality. Examination of the 3-D structure allows the
protein to exhibit conformations that may reveal details
of its structure and help understand its activity [13]. Con-
formational changes occur via distinct molecular
domains, as defined by their binding to monoclonal anti-
body fragments. However, a flat 2-D surface offers less
binding capacity than a 3-D structure, thus increasing con-
siderably the sensitivity of measurement [15]. Moreover,
the 3-D structure yields superior signal over a flat substrate
and enhances the quantity of adsorbed protein per unit
area [16]. In this context, metal nanoparticles could serve
as potential carriers and/or anchor materials for biomole-
cules. Magnetic nanoparticles for example have been
reported as support structures for biological materials
including proteins, peptides, enzymes, DNA, because of
their uniqueness [17-19]. Magnetically labeled molecules
could be directed or driven to a specific location in a bio-
logical system using suitable magnetic fields. However,
aggregation is a known problem when utilizing magnetic
nanoparticles. While magnetic nanoparticles have unique
advantages, considerable attention has also been placed
on the functionalization of gold nanoparticles because of
their excellent biocompatibility and established synthesis
protocols. Furthermore, the possible application of thiol
chemistry on gold surface allows the attachment of mole-
cules with relative ease using various thiol linkers [20-23].
Hence, when magnetic nanoparticles are coated with a
gold shell, the magnetic character and attributes could be
preserved, and all the benefits of gold surfaces could be
harnessed in the areas of biosensors and bioseparations
when such a biocomplex is functionalized.
In the present study, we report the kinetics of binding of
prion protein to magnetic and gold coated magnetic nan-
oparticles, after modification of the surface chemistries of
these materials. The modification of magnetic nanoparti-
cles consists of the chemosorption of L-aspartic acid
(LAA), while gold coated magnetic nanoparticles were car-
boxylated using mercaptopropionic acid. The binding of
prion protein to the particles was achieved directly after
the activation of carbodiimide in the presence of N-
hydroxysuccinimide. The change in the rate of binding in
response to the variation of the protein density in the reac-
tion medium was also examined.
Results and discussion
The particles generally have a spherical shape and span a
distribution of particle sizes. The Fe3O4@Au nanoparti-
cles were bigger and are in the range between 8 and 13 nm
while Fe3O4-LAA were between 5 and 9 nm. The differ-
ence in size is attributable to the gold coating, assuming
that the gold shell around the magnetic particles contrib-
utes to an increase in size. TEM images of Fe3O4@Au nan-
oparticles (a) and huPrPrec functionalized gold coated
magnetic nanoparticles (Fe3O4@Au-huPrPrec) (b) are
shown in Figure 1, and Fe3O4-LAA nanoparticles (a) and
huPrPrec functionalized magnetic nanoparticles – Fe3O4-
LAA-huPrPrec (b) are shown in Figure 2. The presence of
the gold shell around the magnetic nanoparticles was con-
firmed by the difference in absorption spectra of pure gold
and Fe3O4@Au colloid prepared in the same way. The
absorption band of the gold colloid was noted to have its
maximum at 528 nm, while the Fe3O4@Au colloid exhib-
ited a maximum at 558 nm (Figure 3). Results obtained
were consistent with that reported by Jun et al. [22] and
Rivas et al. [24] for the absorption maximum (526 nm) of
pure gold colloid, while the absorption maximum for the
Fe3O4@Au was consistent with the value reported by Jun
et al. [22].
The incorporation of carboxyl groups onto the
Fe3O4@Au particles consisted of placing the nanoparti-
cles for two nights in an ethanolic solution of 3-MPA to
allow binding to occur between the gold surface and the
thiol group via the well known thiol chemistry. For theJournal of Nanobiotechnology 2006, 4:8 http://www.jnanobiotechnology.com/content/4/1/8
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functionalization of magnetic nanoparticles, LAA was
chemisorbed [23] onto the particle surface to provide a
particle surface with carboxyl and amino groups. These
groups were further activated by carbodiimide for the
immobilization of prion protein. Figure 4 describes the
chemisorption of LAA onto Fe3O4 (a), the carboxylation
of Fe3O4@Au using mercaptopropionic acid (b) and the
immobilization of prion protein onto the particles using
the carbodiimide bridge. Briefly, the magnetic nanoparti-
cles were activated with nitric acid to favor the attachment
of L-aspartic acid bearing carboxyl groups onto the mag-
netic nanoparticles. The formation of amide bonds
between carboxylic acids and amines was catalyzed by car-
bodiimide which activates the carboxyl groups on the
linkers to form O-urea derivatives. Succinctly, addition of
N-hydroxysuccinimide catalyzed the formation of the
intermediate active esters that further reacts with the
amine function of the prion protein to yield the amide
bond between the protein and the carboxyl groups on the
particles.
FTIR
The adsorption of monolayers and biofunctionalization
of nanoparticles were qualitatively assessed by FTIR spec-
troscopy. Figure 5 shows the FTIR spectra of Fe3O4@Au,
Fe3O4-LAA, huPrPrec, Fe3O4@Au-huPrPrec, and Fe3O4-
LAA-huPrPrec. The coating of Fe3O4@Au and Fe3O4 with
carboxyl groups and LAA was noted by the appearance of
various peaks in the regions from 1400 to 1650 cm-1 in the
spectra of Figure 5a and 5b. The multitude of small peaks
crowding the spectra with features associated with various
functional groups hinder identification of peaks specific
TEM images and particle sizes distribution of gold coated magnetic nanoparticles- Fe3O4@Au (a) and huPrPrec functionalized  gold coated magnetic nanoparticles- Fe3O4@Au-huPrPrec (b) Figure 1
TEM images and particle sizes distribution of gold coated magnetic nanoparticles- Fe3O4@Au (a) and huPrPrec functionalized 
gold coated magnetic nanoparticles- Fe3O4@Au-huPrPrec (b).
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to carbonyl and amine groups in the chemisorbed regions
making the differentiation between Fe3O4@AuCOOH
(Fe3O4@Au bearing carboxyl groups) and Fe3O4-LAA dif-
ficult. Spectra in Figure 5c depicts the functional groups
related to pure huPrPrec via characteristic bands of pro-
teins at 1490, 1541, and 1645 cm-1 wave numbers assign-
able to the symmetric stretching of the dissociated
carboxylic group originating from the amino acid, amide
I and amide II as shown in the spectra of Figure 5d and 5e.
In the 1415-1300 cm-1 region of the spectra in Figure 5c, d
and 5e a weak band typical to the spectra of the carboxy-
late group attributable to proteins was also noted. The
presence of protein characteristics on the spectra of pure
huPrPrec and on the spectra of Fe3O4@AuCOOH-
huPrPrec, Fe3O4-LAA-huPrPrec confirmed that huPrPrec
was effectively bound to the nanoparticles.
Binding kinetics
huPrPrec was immobilized onto functionalized
Fe3O4@Au and Fe3O4-LAA particles after activation by
EDC in the presence of NHS. The amount of huPrPrec was
determined spectrophotometrically using different con-
centrations of huPrPrec. The rate of binding expressed as
the change in the concentration of unbound protein in
the reaction medium was measured using a linear regres-
sion analysis of the plots of huPrPrec concentration as a
function of time. The coefficient of variation between rep-
licates was less than 4%. Figure 6a, b, c, d, e and 6f show
plots of the decrease in huPrPrec when the initial concen-
trations were 1, 1.5, 2, 2.25, 3.75, and 5 μg/ml, respec-
tively. Rate constants of huPrPrec presented in table 1
shows an increase in the initial concentration of prion
protein from approximately 0.06 to 0.194 h-1, and 0.058
TEM images and particle sizes distribution of magnetic nanoparticles- Fe3O4-LAA (a) and huPrPrec functionalized magnetic nan- oparticles Fe3O4-LAA- huPrPrec (b) Figure 2
TEM images and particle sizes distribution of magnetic nanoparticles- Fe3O4-LAA (a) and huPrPrec functionalized magnetic nan-
oparticles Fe3O4-LAA- huPrPrec (b).
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to 0.212 h-1 for Fe3O4@Au and Fe3O4-LAA, respectively,
in the range of huPrPrec concentrations tested. For each
concentration of protein, the rate constant was about the
same, irrespective of the type of nanoparticles, except
when a concentration of 5 μg/ml of huPrPrec was used.
The binding occurred gradually and reached approxi-
mately 94%, 87%, 65%, 73%, 79%, and 74% for
Fe3O4@Au and 94%, 87%, 67%, 73%, 81%, and 71% for
Fe3O4-LAA, when the initial concentrations of huPrPrec
were 1.5, 2, 2.25, 3.75, and 5 μg/ml, respectively, after 20
h of reaction. Figure 7 show plots of the rate constant as a
function of the initial concentration of huPrPrec. The
trend observed shows that the rate constant increased
exponentially with the initial concentration of huPrPrec.
Fischer et al. [25] immobilized the disease associated
prion protein using 0.1 mg/ml of reacting prion protein
for immobilizing the disease associated prion protein
solution onto magnetic beads. Here, we were able to
quantify down to 0.6 % of 1 μg/ml of reacting huPrPrec.
The low concentration of huPrPrec coupled to the
increase in the binding rate constants observed with
increased protein concentration suggests that the detec-
tion methodology is sensitive. Table 2 shows the percent-
age of huPrPrec binding to the nanoparticles. The trend
was quite similar for the immobilization carried out using
both carriers although the overall binding rate constants
were slightly higher in Fe3O4-LAA than the Fe3O4@Au
conjugates. This indicated that binding was slightly more
effective when Fe3O4-LAA complex was used. The bigger
sizes of Fe3O4@Au should have favored the rate of bind-
ing since it offers a greater surface area, but this is not the
case here where Fe3O4-LAA exhibited a better binding
affinity. The difference in the affinity of binding could be
attributed to the fact that LAA possess amino acids that
originated from the protein that may exhibit higher affin-
ity to the surface of the particles. The difference in the rate
constants observed at this concentration may be associ-
ated with the difference in functional groups on the sur-
face of the nanoparticles used. Prion protein is a complex
entity, and although numerous binding partners have
been found for the protein, its function still remains
unclear, since each portion of the protein has its own
functional properties [26]. Although significant effort has
been made in elucidating prion related diseases, numer-
ous questions on the structure and conformation of the
protein are still to be answered. Huang et al [16] demon-
strated that immobilizing specific proteins onto magnetic
nanoparticles allows the molecules to expand and acquire
a better conformation that could lead to an improved
activity. As the possibility to move magnetic nanoparticles
using an external magnetic field is an essential asset for
molecular manipulation for diagnosis purposes, the
immobilization of prion protein onto magnetic and gold
coated magnetic nanoparticles and the kinetics data
obtained in this study may contribute to an improved bio-
logical assay in which the protein could be directed
toward target locations such as monoclonal prion protein
antibodies [8] by appropriate directed magnetic fields.
Furthermore, data on binding kinetics can be useful in the
design and evaluation of molecular carriers and in the
measurement of the efficacy of the surface chemistry
developed. Developing methodologies for attachment of
prion protein to magnetic nanoparticles can also contrib-
ute to enhancing in vivo and in vitro manipulation of the
molecules which is essential in elucidating the structure of
the protein and the resulting activity.
Conclusion
We have demonstrated the possibility of immobilizing
huPrPrec onto magnetic and gold coated magnetic nano-
particles by functionalization of these particles with
appropriate chemistry to bear carboxyl groups. The
immobilization methodologies developed in this study
and the information on prion binding kinetics will be use-
ful for sensitive and label-free detection of prion proteins,
and will be helpful in the assessment of the physiological
and pathological condition of these proteins. We also
envision that the immobilization methodologies dis-
cussed could be applied for rapid identification, epidemi-
ological studies, genetic evaluation, and forensic
investigation.
Optical properties of pure gold solution and gold coated  magnetic nanoparticles Figure 3
Optical properties of pure gold solution and gold coated 
magnetic nanoparticles. The absorption maxima were found 
at 520 and 558 nm for Au and Fe3O4@Au, respectively.
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Methods
Preparation of magnetic nanoparticles
Iron (II) chloride tetrahydrate 97 %, iron (III) chloride
hexahydrate 99%, sodium hydroxide, acetic anhydride,
nitric acid, 1-butanol, octane, toluene, methanol, L-aspar-
tic acid (LAA), cetyltrimethylammonium bromide
(CTAB), 3-mercaptopropionic acid (3-MPA), sodium tet-
rahydridoborate (NaBH4), and Phosphate Buffer Saline
Functionalization of magnetic and gold coated magnetic nanoparticles: the chemisorption of LAA onto Fe3O4 (a), the carboxy- lation of Fe3O4@Au using mercaptopropionic acid (b), the activation of the carboxyl groups on the particle, the formation of  N-hydroxysuccinimidyl ester in the presence of EDC (c), and the immobilization of huPrPrec onto particles (d) Figure 4
Functionalization of magnetic and gold coated magnetic nanoparticles: the chemisorption of LAA onto Fe3O4 (a), the carboxy-
lation of Fe3O4@Au using mercaptopropionic acid (b), the activation of the carboxyl groups on the particle, the formation of 
N-hydroxysuccinimidyl ester in the presence of EDC (c), and the immobilization of huPrPrec onto particles (d). R1 denotes 
nanoparticles.
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(PBS), pH 7.4 were obtained from Sigma-Aldrich Inc. (St
Louis, USA). Hydrogen tetrachloroaurate (III) hydrate
(HAuCl4) was obtained from Sigma-Aldrich Inc. (Milwau-
kee, WI). Streptavidin, a strain of Streptomyces avidini was
purchased from Sigma-Aldrich Inc. (MO, USA) and 1-
ethyl 3-(3-dimethylaminepropyl) carbodiimide hydro-
chloride (EDC) from Pierce (Rockford, IL, USA) was used
to complete the streptavidin-biotin reaction in the pres-
ence of N-hydroxysuccinimide (NHS) (Sigma-Aldrich,
Allentown, PA). Human recombinant prion protein histi-
dine-tagged (23–231), huPrPrec was obtained from
Abcam Inc (Cambridge, MA).
Preparation of Fe3O4 magnetic nanoparticles
Magnetic nanoparticles Fe3O4 were prepared by hydro-
thermal co-prepcipitation of ferric and ferrous using
NaOH as a base as described by Kouassi et al [21]. Typi-
cally iron (II) chloride and iron (III) chloride (1:2) were
dissolved in nanopure water at a concentration of 0.25 M
iron ions and chemically precipitated at room tempera-
ture (25°C) by repeatedly adding 1 M NaOH to maintain
a constant pH of 10. The precipitates were heated at 80°C
for 35 min under continuous mixing and washed 4 times
in water and several times in ethanol. During washing, the
magnetic nanoparticles were separated from the washing
liquid using a magnetic separator of strength greater than
20 megaoersted (MOe). The particles were finally dried in
a vacuum oven at 70°C.
Synthesis of gold-coated magnetic nanoparticles 
(Fe3O4@Au)
Fe3O4@Au were prepared using reverse micelle of CTAB
using 1-butanol as a cosurfactant and octane as the oil
phase by modification of the procedure developed by Jun
et al. [22]. The size of the reverse micelle is dependent on
the molar ratio of water to surfactant. In this work, parti-
cles were prepared by choosing a molar ratio of water to
CTAB, w as [H20]/[CTAB] = 8. The procedure and compo-
nents of the experiment were described by Jun et al. [19].
To a 2.5 ml of solution A containing 1 M FeCl3, 0.5 M
FeCl2, 0.17 mole of CTAB, 0.7 mole of butanol, and 0.17
mole of octane, was added a 2.5 ml of solution B contain-
ing 1 M NaBH4 and the same composition of CTAB, buta-
nol, and octane as in solution A. The blend was heated at
60°C while vigorously mixing for 20 min to form mag-
netic nanoparticles. A 2 ml amount of a solution C con-
taining 0.44 mole of HAuCl4, 0.8 mole of CTAB, 0.25
mole butanol, and 0.011 mole octane and an equivalent
volume of a solution D containing 1.6 M NaBH4, 0.8
mole of CTAB, 0.25 mole of butanol, and 0.11 mole of
octane were successively added. The pH was kept at 11 by
adding minute amounts of 0.5 M NaOH. The mixture was
continuously mixed for 15 minutes. The gold coated mag-
netic nanoparticles formed were washed four times with
water, several times with methanol and dried in a vacuum
oven for 6 h. To demonstrate that a gold layer was formed
around the magnetic nanoparticles, gold colloidal and
Fe3O4@Au solutions were prepared by dissolving 1.5 mg
of HAuCl4 and Fe3O4@Au, respectively, in 4 ml of water
and the absorbance was measured using a UV-Vis Beck-
man Du spectrophotometer.
LAA functionalization of magnetic nanoparticles
1.5 g of magnetic nanoparticles was immersed in 50 ml of
0.1 M LAA solution prepared in nitric acid of pH ≈ 2. The
mixture was sonicated for 15 min and vigorously stirred
for 10 h at room temperature. An external magnetic field
was applied to recover the particles and washed two times
with nanopure water. The process is expected to ensure
the chemisorption of aspartic acid, bearing carboxyl and
amino groups onto the surface of the particles.
Carboxylation of gold coated magnetic nanoparticles 
Fe3O4@Au
The carboxylation of gold coated magnetic nanoparticles
was done to allow the formation of amide bond between
carboxyl groups on the surfaces of the nanoparticles with
amino groups from the protein molecules. Magnetic nan-
oparticles (1.5 g) were added to 15 ml ethanolic solution
of 3-MPA 20 mM, sonicated for 48 h and rinsed in nano-
pure water and dried in a vacuum oven for 6 h.
Immobilization of prion protein (huPrPrec) onto magnetic 
and gold coated magnetic nanoparticles
One mg of EDC, 1.2 mg of NHS and 8 mg of carboxyl or
LAA functionalized particles were added to 3 ml phos-
phate buffer solution (pH 7.4) containing 3–15 μg of
huPrPrec. The mixture was then sonicated at 4°C for 10
FTIR spectra of Fe3O4@Au (a), Fe3O4-LAA (b) huPrPrec (c),  Fe3O4@Au-huPrPrec (d) Fe3O4-LAA-huPrPrec(e) Figure 5
FTIR spectra of Fe3O4@Au (a), Fe3O4-LAA (b) huPrPrec (c), 
Fe3O4@Au-huPrPrec (d) Fe3O4-LAA-huPrPrec(e).
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Plots of huPrPrec binding onto Fe3O4@Au and Fe3O4-LAA (a) as a function of time for various concentrations of huPrPrec Figure 6
Plots of huPrPrec binding onto Fe3O4@Au and Fe3O4-LAA (a) as a function of time for various concentrations of huPrPrec.
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min and continuously shaken for 18 h at room tempera-
ture. At 4 h time intervals a magnetic separator was used
to separate the particles from the reaction medium and 30
μl of the reacting solution was taken and used for the
determination of protein content using the Bio-Rad Pro-
tein Assay using human IGg as the protein standard. Por-
tion of the particles were taken and washed with PBS to
separate unbound protein from the particle surfaces and
used for characterization.
Binding kinetics
The concentration of protein in the supernatant was mon-
itored every four hours for a period of twenty hours to
evaluate the concentration of bound huPrPrec and the
rate constants were determined using linear regression
analysis from the plot of protein concentration versus
time. Each point is the average of two measurements. The
sensitivity of the assay was demonstrated by examining
the dose response of the rate constant versus huPrPrec
concentration in the concentration range between 2 and 5
μg/ml.
Characterization
The sizes of magnetic and gold coated magnetic nanopar-
ticles were characterized by transmission electron micros-
copy (TEM, JEM 1200 EXII, JEOL) and the attachment of
biomolecules qualitatively by FTIR spectroscopy (Biorad
FTS 6000, Cambridge, MA). The samples for TEM analysis
were prepared as follows: a drop of magnetic nanoparti-
cles was dispersed in nanopure water and the resulting
solution was sonicated for 5 min to obtain better particle
dispersion characteristics. A drop of the dispersed solu-
tion was then deposited onto a copper grid and dried
overnight at room temperature. Confirmation of the
binding of huPrPrec onto the magnetic nanoparticles was
done using FTIR spectroscopy. Nanoparticles bearing
huPrPrec obtained after the immobilization procedure
were separated using a magnetic separator and washed
with PBS to remove unbound huPrPrec. A small amount
of the remaining huPrPrec-magnetic nanoparticle conju-
gates were mixed in 5 ml of PBS and a drop of the mixture
was deposited on the FTIR micro-ATR sample holder for
analysis.
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